Capricor acquires Medtronic patents to boost heart failure treatments
Biotechnology company Capricor Therapeutics has agreed to acquire patents from medical equipment maker Medtronic as part of plans to develop a programme to treat heart failure.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
23 September 2021 The US Patent Trial and Appeal Board has confirmed the validity of three remaining Medtronic patents challenged by rival medical device manufacturer Axonics.
23 September 2021 The US Patent Trial and Appeal Board has confirmed the validity of three remaining Medtronic patents challenged by rival medical device manufacturer Axonics.
23 September 2021 The US Patent Trial and Appeal Board has confirmed the validity of three remaining Medtronic patents challenged by rival medical device manufacturer Axonics.